ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104 | +60.0% | 9,126 | +44.3% | 0.00% | – |
| Q2 2023 | $65 | -30.1% | 6,325 | -47.6% | 0.00% | – |
| Q1 2023 | $93 | +106.7% | 12,079 | +98.7% | 0.00% | – |
| Q4 2022 | $45 | -99.1% | 6,080 | +818.4% | 0.00% | – |
| Q3 2022 | $5,000 | -28.6% | 662 | -15.5% | 0.00% | – |
| Q2 2022 | $7,000 | -58.8% | 783 | -58.5% | 0.00% | – |
| Q1 2022 | $17,000 | -95.7% | 1,886 | -93.3% | 0.00% | – |
| Q4 2021 | $392,000 | +668.6% | 28,196 | +494.0% | 0.00% | – |
| Q3 2021 | $51,000 | +292.3% | 4,747 | +223.1% | 0.00% | – |
| Q2 2021 | $13,000 | -91.3% | 1,469 | -89.6% | 0.00% | – |
| Q1 2021 | $150,000 | +500.0% | 14,105 | +405.0% | 0.00% | – |
| Q3 2020 | $25,000 | – | 2,793 | +139550.0% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 2 | -98.5% | 0.00% | – |
| Q1 2018 | $1,000 | – | 134 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |